Onco Wiki / drapeau rouge

HHV-8 (herpèsvirus associé au sarcome de Kaposi, KSHV) séropositivité dans une immunodétermination...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-CHRONIC-HHV8-MALIGNANCY-PREVENTION
TypeSignal d’alerte
Étatreviewed 2026-05-18 | pending_clinical_signoff
MaladiesDIS-KAPOSI
SourcesSRC-IARC-MONO-100B-2012 SRC-NIH-AIDS-2024

Origine du drapeau rouge

DéfinitionHHV-8 (Kaposi sarcoma-associated herpesvirus, KSHV) seropositivity in an immunocompromised host (HIV+, solid-organ-transplant recipient on chronic immunosuppression, or other persistent T-cell-immunity deficit) without a current Kaposi sarcoma, multicentric Castleman disease (MCD), or primary effusion lymphoma (PEL) diagnosis. IARC Group 1 carcinogen (HHV-8) — established etiological driver of all three lymphoproliferative outcomes. No curative antiviral exists; the prevention pathway is restoration / optimization of cellular immunity (ART initiation for HIV+; minimization of immunosuppression where transplant-graft-safe) plus mucocutaneous + oral + GI awareness and lymph-node surveillance. Prevention-persona RedFlag (§20 ratification 2026-05-18).
Direction cliniqueenquêter
Catégorieautres

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "hhv8_serology",
      "value": "positive"
    },
    {
      "finding": "kshv_serology",
      "value": "positive"
    },
    {
      "finding": "hhv8_status_in_immunocompromised",
      "value": "positive"
    }
  ],
  "type": "lab_value"
}

Notes

Prevention-persona RedFlag for HHV-8-driven malignancy prevention. Fires on HHV-8 seropositivity in HIV+, transplant, or other immunocompromised host without confirmed Kaposi sarcoma / MCD / PEL. Engine routes to PreventionPlan recommending immune restoration (ART for HIV+; transplant-immunosuppression rebalance) + mucocutaneous + oral + GI / lymph-node surveillance. STUB pending Co-Lead review. Cancer scope: anchored to DIS-KAPOSI. MCD and PEL are HHV-8-driven but not yet authored as distinct Disease entities — covered via the prose surveillance rationale in the indication for now. Distinct from RF-CHRONIC-HIV-MALIGNANCY-PREVENTION (existing) — that is HIV-as-RF; this is HHV-8-positivity-as-RF (the co-factor that turns HIV-related immunocompromise into Kaposi risk specifically).

Utilisé par

Indication

Signal d’alerte